Nephrocare Health Services Limited IPO
Nephrocare Health Services Limited IPO
Nephrocare Health Services Limited IPO
₹ 14720 / 32 Shares Shares
Minimum Investment
Nephrocare Health Services Limited IPO
Issues Price
₹438-460 per equity share
Nephrocare Health Services Limited IPO
Open Date
10 Dec 2025
Close Date
12 Dec 2025
Lot Size
16
Min. Investment
₹ 14720
Issue Price
₹438-460
Listing Date
17 Dec 2025
Issues Size
1,89,35,819 shares(aggregating up to ₹871.05 crore)
Face Value
₹2 Per Equity Share
Total Shares Offered
32 Shares
Offered To Public
32 Shares
Nephrocare Health Services Limited IPO
Nephrocare Health Services Ltd, incorporated in the year 2010, is an end-to-end dialysis care provider through its wide network of clinics across India and select international markets. It offers services such as diagnosis, haemodialysis, home and mobile dialysis, and wellness programs, supported by an in-house pharmacy. As of March 31, 2025, Nephrocare operated 490 clinics—447 in India and 43 across the Philippines, Uzbekistan, and Nepal. This includes the world’s largest dialysis clinic in Uzbekistan. In India, the company had a presence across 269 cities in 21 States and four Union Territories. Approximately 76.73% of its clinics were located in tier II and tier III cities, addressing a critical need in underserved regions. In Fiscal 2025, Nephrocare treated 29,281 patients and performed more than 2.88 million dialysis treatments, amounting to approximately 10% of the country's total dialysis patient base. The number of dialysis machines operated by the company increased to 5,068 as of March 2025 from 4,714 in Fiscal 2024 and 3,662 in Fiscal 2023. Nephrocare has formulated strategic alliances with leading hospital chains like Max Super Speciality Hospital, Fortis Escorts Hospitals, Care Hospitals, Wockhardt Hospitals, Paras Healthcare, The Calcutta Medical Research Institute, Jehangir Hospital, and Ruby Hall Clinic to operate in-house dialysis centers. As of March 2025, the workforce consisted of 3,230 employees, including both medical and administrative staff working across its clinics and corporate office.
Founded In
2010
Managing Director
Vikram Vuppala
Parent Organization
Nephrocare Health Services Limited IPO
Application for Nephrocare Health Services Limited IPO
| Apply as | Price Range | Apply Upto |
|---|---|---|
| Retail (min) | ₹438-460 | ₹14,720 |
| Retail(max) | ₹438-460 | ₹1,91,360 |
| SHNI(min) | ₹438-460 | ₹2,06,080 |
| SHNI(max) | ₹438-460 | ₹9,86,240 |
| BHNI(min) | ₹438-460 | ₹10,00,960 |
Apply for all eligible candidates, Nephrocare Health Services Limited IPO.
Open On12 Dec 2025
Close On16 Dec 2025
Price Range₹2061-2165
Testimonial
Genuine Review Form Statisifed Customers
Thanks to KSquare, I purchased my first car without loans. The SIP plan was perfectly calculated and aligned with my budget, making everything financially smooth and stress-free.
I always wanted to invest in mutual funds but felt overwhelmed. KSquare made everything so simple. Their expert suggestions helped me start confidently and stay informed.
KSquare made mutual fund investing enjoyable. I track everything on one dashboard and have learned a lot through their educational resources. Perfect for professionals.
KSquare helped me plan my retirement with complete clarity. The SIP guidance was simple, personalised, and stress-free. I now feel financially confident about my future and family responsibilities.
KSquare’s pension guidance was much needed. Their team helped me select the right NPS tier and gave detailed explanations.
KSquare’s NRI Corner made investing from abroad incredibly simple. The guidance was crystal clear, and their support team always kept me informed. Highly recommend this service for all NRIs!
Owning a home seemed difficult, but KSquare’s SIP planning made it achievable. Their regular guidance, timely suggestions, and disciplined investment approach gave me complete financial confidence throughout the journey.
Thanks to KSquare, I’ve finally started saving regularly. Their SIP structure fits my needs, and I feel much more confident about my financial future.
KSquare’s approach to New Fund Offerings really impressed me. I finally feel confident participating in something I once thought was too complicated.
Being self-employed, I wanted a structured way to invest. KSquare’s SIPs fit the bill. It’s affordable, effective, and easy to track progress over time.
FAQ's
Frequenlty Asked Question
How does SIP-to-SWP second income planning work?
SIPs help build a corpus first, later converted to monthly withdrawable income through SWP, ensuring reliable financial independence
Can I nominate someone in India for my investments?
Yes, NRIs can nominate any Indian resident for their mutual fund holdings and other financial assets via KSquare.
Will I lose ownership of my mutual funds?
No, the mutual funds are just pledged. You continue to retain ownership and can repay the loan to unpledge them.
Do SIPs help in achieving children’s education goals?
Yes, SIPs offer structured savings and growth, ensuring funds are ready when needed for future school, college or career plans.
Can I invest in an NFO online with KSquare?
Yes, KSquare’s digital platform enables secure and quick online investments in NFOs with just a few clicks.
Can I nominate someone for my NPS account?
Yes, nomination is mandatory and can be easily added or updated through your KSquare profile.
Can I have multiple SIPs for different goals?
Yes, you can set up multiple SIPs with KSquare for various goals like retirement, education, or buying a home.
Does KSquare provide research reports on NFOs?
Yes, KSquare offers fund highlights, investment strategy, and expert opinions to help you evaluate each NFO thoroughly.
Ksquare Timeline Pvt. Ltd. is an AMFI Registered Mutual Fund Distributor having ARN No. 146262. Mutual Fund investments are subject to market risks. Please read all scheme related documents carefully before investing. This website is intended only for informational and self-help purposes and should not be considered as investment advice or return guarantee. Past performance is not indicative of future results. Terms & Conditions apply.